These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1450288)

  • 1. Shifts in covert visual attention in schizophrenic patients and normal controls.
    Moran MJ; Thaker GK; Smith D; Cassady S; Layne-Gedge J
    Biol Psychiatry; 1992 Oct; 32(7):617-20. PubMed ID: 1450288
    [No Abstract]   [Full Text] [Related]  

  • 2. Continuous performance tests in schizophrenic patients: stimulus and medication effects on performance.
    Earle-Boyer EA; Serper MR; Davidson M; Harvey PD
    Psychiatry Res; 1991 Apr; 37(1):47-56. PubMed ID: 1862161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication may be required for the development of automatic information processing in schizophrenia.
    Serper MR; Bergman RL; Harvey PD
    Psychiatry Res; 1990 Jun; 32(3):281-8. PubMed ID: 2388967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cognition and driving in schizophrenic patients under treatment with risperidone vs. haloperidol].
    Dittert S; Soyka M; Winter C; Möller HJ
    Fortschr Neurol Psychiatr; 1999 Nov; Suppl 2():S70-3. PubMed ID: 10598340
    [No Abstract]   [Full Text] [Related]  

  • 5. Prediction of response to haloperidol dose reduction by Span of Apprehension measures for treatment-refractory schizophrenic patients.
    Green MF; Mintz J; Bowen L; Marshall BD; Kuehnel TG; Hayden JL; Liberman RP
    Am J Psychiatry; 1993 Sep; 150(9):1415-6. PubMed ID: 8352355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia.
    Zahn TP; Pickar D; Haier RJ
    Schizophr Res; 1994 Sep; 13(2):133-44. PubMed ID: 7986770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative symptoms and reaction time in schizophrenia.
    Schwartz F; Munich RL; Carr A; Bartuch E; Lesser B; Rescigno D; Viegener B
    J Psychiatr Res; 1991; 25(3):131-40. PubMed ID: 1941709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P300, clinical symptoms, and neuropsychological parameters in acute and remitted schizophrenia: a preliminary report.
    Eikmeier G; Lodemann E; Zerbin D; Gastpar M
    Biol Psychiatry; 1992 May; 31(10):1065-9. PubMed ID: 1511077
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of antipsychotic drugs and symptomatology on perceptual asymmetry in schizophrenia.
    Carr V; Wale J
    J Neurol Neurosurg Psychiatry; 1988 Dec; 51(12):1531-7. PubMed ID: 2906089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of illness duration on perceptual asymmetry in schizophrenia.
    Carr V; Wale J; Dewis S; Stephan L
    Schizophr Res; 1992 Sep; 7(3):211-6. PubMed ID: 1356424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analysis of reaction time in post-acute schizophrenia using electrophysiologic variables].
    Eichert V; Klosterkötter J
    Fortschr Neurol Psychiatr; 1996 Jul; 64(7):261-70. PubMed ID: 8765892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine and negative symptoms.
    Wing YK
    Br J Psychiatry; 1993 Jul; 163():121. PubMed ID: 8353681
    [No Abstract]   [Full Text] [Related]  

  • 13. Clozapine decreases smoking in patients with chronic schizophrenia.
    McEvoy J; Freudenreich O; McGee M; VanderZwaag C; Levin E; Rose J
    Biol Psychiatry; 1995 Apr; 37(8):550-2. PubMed ID: 7619979
    [No Abstract]   [Full Text] [Related]  

  • 14. Covert visual attention in schizophrenia spectrum personality disordered subjects: visuospatial cuing and alerting effects.
    Moran MJ; Thaker GK; Laporte DJ; Cassady SL; Ross DE
    J Psychiatr Res; 1996; 30(4):261-75. PubMed ID: 8905535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of atypical neuroleptics on alertness and visual orienting in stabilized schizophrenic patients: a preliminary study.
    Daban C; Krebs MO; Bourdel MC; Willard D; Loo H; Olié JP; Poirier MF; Amado I
    Int J Neuropsychopharmacol; 2004 Sep; 7(3):255-63. PubMed ID: 15050039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.
    Volavka J; Nolan KA; Kline L; Czobor P; Citrome L; Sheitman B; Lindenmayer JP; McEvoy J; Lieberman JA
    Schizophr Res; 2005 Jul; 76(1):127-9. PubMed ID: 15927808
    [No Abstract]   [Full Text] [Related]  

  • 17. Increased blink rate in drug-naive acute schizophrenic patients.
    Mackert A; Woyth C; Flechtner KM; Volz HP
    Biol Psychiatry; 1990 Jun; 27(11):1197-202. PubMed ID: 2354226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of neurological signs with clozapine treatment.
    Buchanan RW; Koeppl P; Breier A
    Biol Psychiatry; 1994 Aug; 36(3):198-200. PubMed ID: 7948457
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of clozapine on psychogenic polydipsia in chronic schizophrenia.
    Lee HS; Kwon KY; Alphs LD; Meltzer HY
    J Clin Psychopharmacol; 1991 Jun; 11(3):222-3. PubMed ID: 2066464
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
    Soyka M; Winter C; Kagerer S; Brunnauer M; Laux G; Möller HJ
    J Psychiatr Res; 2005 Jan; 39(1):101-8. PubMed ID: 15504428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.